Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands,
Stem Cell Rev Rep. 2014 Jun;10(3):389-98. doi: 10.1007/s12015-014-9502-7.
The majority of patients survive an acute myocardial infarction (AMI). Their outcome is negatively influenced by post-AMI events, such as loss of viable cardiomyocytes due to a post-AMI inflammatory response, eventually resulting in heart failure and/or death. Recent pre-clinical animal studies indicate that mesenchymal stem cells derived from adipose tissue (ASC) are new promising candidates that may facilitate cardiovascular regeneration in the infarcted myocardium. In this review we have compared all animal studies in which ASC were used as a therapy post-AMI and have focused on aspects that might be important for future successful clinical application of ASC.
大多数急性心肌梗死（AMI）患者能够存活下来。AMI 后发生的事件会对他们的预后产生负面影响，如由于 AMI 后的炎症反应导致的存活心肌细胞丧失，最终导致心力衰竭和/或死亡。最近的临床前动物研究表明，来源于脂肪组织的间充质干细胞（ASC）是一种新的有前途的候选细胞，可能有助于梗死心肌中的心血管再生。在这篇综述中，我们比较了所有使用 ASC 作为 AMI 后治疗的动物研究，并重点关注了可能对 ASC 未来成功的临床应用重要的方面。
